

IFW B

Dkt. 43016-A-PCT-US/JPW/JW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Philip O. Livingston and Friedhelm Helling
Serial No.: 08/196,154 Examiner: A. Holleran
Filed : November 16, 1995 Group Art Unit: 1642
For : GANGLIOSIDE-KLH CONJUGATE VACCINES PLUS
QS-21

1185 Avenue of the Americas
New York, New York 10036
September 28, 2005

MAIL STOP ISSUE FEE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

AMENDMENT PURSUANT TO 37 C.F.R. §1.312

This Amendment is submitted pursuant to 37 C.F.R. §1.312. According to 37 C.F.R. §1.312, an Amendment after a Notice of Allowance must be filed before or with the payment of the issue fee. Applicants are concurrently paying the issue fee. Accordingly, this Amendment is being timely filed.

Please amend the subject application as follows:



Amendments to the Brief Description of the Figures

Please replace the paragraph beginning at page 5, line 4, with the following amended paragraph:

Figure 1A-1B 1A and 1B: The synthesis of GD3 protein conjugates after ozone cleavage and reductive amination. Insert represents HPTLC of GD3 before (lane A) and after (lane B) the cleavage.

Please replace the paragraph beginning at page 6, line 11, with the following amended paragraph:

Figures ~~8A-1 and 8A-2~~ 8A - 8B

8A and 8B: Specificity of peak titer sera from patients immunized GM2-KLH + QS-21 vaccine determined by immune thin layer chromatography as described previously (3, Reference of the Third Series of Experiments). GM2 (A) and melanoma tissue ganglioside extract (B) were applied to TLC plates, incubated with sera from individual patients and stained with peroxidase-labeled goat anti-human IgM or IgG antibody. MAb 696 was used as positive control for GM2 and resorcinol stain for gangliosides.

Please replace the paragraph beginning at page 6, line

24, with the following amended paragraph:

Figure ~~8B~~ 8C

Inhibition of IgG reactivity of patient serum against GM2 and GD2. GM2 (A) and melanoma tissue ganglioside extract (B) were applied to HPTLC plates, incubated with serum from patient No. 2 and stained with peroxidase-labeled goat anti-human IgG antibody. 3ml Patient serum at a dilution of 1:50 was preincubated with either 150µg GM2 or 150µg GD2 prior to Immune staining.

Please replace the paragraph beginning at page 6, line 33, with the following amended paragraph:

Figures 9A, ~~and 9B,~~ 9C, and 9D

IgM and IgG antibody response in melanoma patients after immunization with GM2-KLH plus QS-21 vaccines. Sequential results for six patients receiving the 100 ug QS-21 dose are shown in Figures 9A and 9B ~~Figure 9a~~ and for six patients receiving the 200 ug dose in Figures 9C and 9D ~~Figure 9b~~. Note that one patient in each group received only four vaccinations and was taken off study due to disease progression. Arrows indicate the time of cyclophosphamide (Cy) and GM2-KLH plus QS-21 vaccine injections.